Christophe Piot, MD

Paclitaxel Drug-Coated Balloon After Bare-Metal Stent Implantation, an Alternative Treatment to Drug-Eluting Stent in High Bleeding Risk Patients (The Panelux Trial)

03/28/2019

Christophe Piot , MD;

Jerome Roncalli , MD, PhD;

Matthieu Godin , MD;

Kamel Boughalem , MD;

John Shayne , MD;

Bruno Huret , MD;

Loic Belle , MD;

Max Amor , MD;

Benjamin Faurie , MD, PhD;

Bernard Karsenty , MD;

Florence Leclercq , MD, PhD;

Guillaume Cayla , MD, PhD;

Prolonged dual-antiplatelet therapy in high bleeding risk (HBR) patients undergoing percutaneous coronary intervention can be challenging. We assessed the clinical safety of bare-metal stent implantation followed by drug-coated balloon...

Prolonged dual-antiplatelet...

03/28/2019

Journal of Invasive Cardiology

Original Contribution

Clinical Outcomes in Patients Treated With Biodegradable-Polymer Biolimus-Eluting Stents and 6 Months of Dual-Antiplatelet Therapy: The French eBiomatrix 6-Month DAPT Registry

05/01/2022

Antoine Gommeaux , MD;

Vincent Malquarti , MD;

Denis Angoulvant , MD;

Clauset Cruchon , MD;

Keith G. Oldroyd , MD, MBChB, FRCP;

Christian Spaulding , MD;

Hakim Benamer , MD;

Thierry Lefèvre , MD;

Olivier Varenne , MD;

Janusz Lipiecki , MD;

Rajiv Rampat , MD;

Christophe Piot , MD;

François Brunelle , MD;

Rami el Mahmoud , MD;

Dual-antiplatelet treatment (DAPT) has conventionally been prescribed for 1 year after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. Recent evidence suggests that a duration of only 6 months may be...

Dual-antiplatelet treatment...

05/01/2022

Journal of Invasive Cardiology